z-logo
open-access-imgOpen Access
Benefit of Transcatheter Aortic Valve Replacement in Patients With Paradoxical Low-Flow Low-Gradient Versus High-Gradient Aortic Stenosis and Preserved Left Ventricular Function
Author(s) -
Wassim Mosleh,
Mostafa R. Amer,
Yuewen Ding,
Michael Megaly,
Jeffrey Mather,
Sean McMahon,
Ashish Pershad,
Raymond G. McKay,
Bhaskar Arora
Publication year - 2021
Publication title -
circulation cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.621
H-Index - 95
eISSN - 1941-7632
pISSN - 1941-7640
DOI - 10.1161/circinterventions.120.010042
Subject(s) - medicine , cardiology , stenosis , aortic valve replacement , dilated cardiomyopathy , valve replacement , aortic valve stenosis , hemodynamics , cardiomyopathy , stroke volume , aortic valve , heart failure , ejection fraction
Background: There is conflicting data regarding transcatheter aortic valve replacement in patients with paradoxical low-flow, low-gradient aortic stenosis (pLFLG-AS). The authors aimed to examine the hemodynamic and clinical benefit of transcatheter aortic valve replacement in symptomatic patients with pLFLG-AS compared with high-gradient severe AS. Methods: A single-center retrospective analysis of patients who underwent transcatheter aortic valve replacement using a transfemoral approach was performed. Patients with a mean gradient ≥40 mm Hg were included in the high-gradient aortic stenosis (HG-AS) group (n=217). Patients with mean gradient <40 mm Hg, Vmax <4.0 m/s, and stroke volume index ≤35 mL/m2 were included in the pLFLG-AS group (n=73). Clinical end points including treatment futility, survival, changes in functional status and quality of life, and echocardiographic outcomes of left ventricular reverse remodeling were evaluated. Two primary composite outcomes were used for treatment futility. The first as a composite outcome defined as death or New York Heart Association class III/IV at 1 year. The second was a composite of death or Kansas City Cardiomyopathy Questionnaire 12 score of ≤25 at 1 year.Results: There were no differences in mortality, the Kansas City Cardiomyopathy Questionnaire-based treatment futility outcome (HG-AS: 8.8% versus pLFLG-AS: 6.1%;P =0.482), or New York Heart Association-based treatment futility outcome (HG-AS: 9.1% versus pLFLG-AS: 11.6%;P =0.546) at 1 year. Both groups had similar improvement in mean Kansas City Cardiomyopathy Questionnaire 12 score when compared to baseline (HG-AS: 88.56±12.38% versus pLFLG-AS: 137.24±31.75%;P =0.382). There was a similar relative interval decrease in the proportion of patients with New York Heart Association class III/IV (HG-AS: 53.6% versus pLFLG-AS: 55.1%;P =0.838). Echocardiographic evidence of reverse remodeling of the left ventricle in pLFLG-AS group was documented by improvements in global longitudinal strain (pre: −13.95±0.36% versus post: −14.83±0.38%,P =0.004) and stroke volume index at 30 days.Conclusions: pLFLG-AS did not confer a worse prognosis. Mortality rate and functional class improvement at 1 year was similar in both groups. Left ventricular reverse remodeling in the pLFLG-AS group was apparent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom